To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Eli Lilly and Co. is suing an Indianapolis-based weight-loss clinic it says is improperly selling Lilly’s hugely popular ...

Eli Lilly shares rose about 5% Tuesday morning after Goldman Sachs upgraded the pharmaceutical giant to Buy from Neutral, ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Following a three-day selloff amid market turmoil attributed to the Trump administration’s sweeping tariffs announced last ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

In the first arrangement of its kind, Eli Lilly to connect patients through telemedicine to providers of Alzheimer’s drugs.

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...